Endpoints News 生物医药· Kyle LaHucik·· 16 天前AI 评分49
勃林格殷格翰与中国信诺生物医药达成70亿美元癌症药物开发协议
Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China's Sino
AI 导读
德国勃林格殷格翰与中国信诺生物医药达成70亿美元的合作协议,专注于癌症药物开发。
正文
Germany’s Boehringer Ingelheim is further planting its stake in China, teaming up with Sino Biopharmaceutical in a cancer drug development deal that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news